Literature DB >> 7077397

16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies.

K D McElvany, J A Katzenellenbogen, K E Shafer, B A Siegel, S G Senderoff, M J Welch.   

Abstract

An estrogen-receptor-binding radiopharmaceutical, 16 alpha-[77Br]bromoestradiol-17 beta, has been used successfully at high specific activity to image carcinogen-induced mammary tumors in rats and in preliminary studies to image breast tumors in patients. The biodistribution of the labeled estrogen in rats and its clearance in a monkey were used to estimate the radiation absorbed doses to a human resulting from administration of the radiopharmaceutical. Preliminary imaging studies in patients with mammary carcinoma show promising results and warrant further development of radiolabeled estrogens, particularly those carrying positron emitters that could permit positron emission tomography--for example Br-75 or F-18.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7077397

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

3.  Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report.

Authors:  J S Lewis; M J Welch; L Tang
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

4.  Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.

Authors:  Dong Zhou; Terry L Sharp; Nicole M Fettig; Hsiaoju Lee; Jason S Lewis; John A Katzenellenbogen; Michael J Welch
Journal:  Nucl Med Biol       Date:  2008-06-30       Impact factor: 2.408

5.  Design, synthesis, and evaluation of cyclofenil derivatives for potential SPECT imaging agents.

Authors:  Hua Zhu; Liliang Huang; Yuanqing Zhang; Xiaoping Xu; Yanhong Sun; Yu-Mei Shen
Journal:  J Biol Inorg Chem       Date:  2010-03-01       Impact factor: 3.358

6.  Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor.

Authors:  Jai Woong Seo; Dae Yoon Chi; Carmen S Dence; Michael J Welch; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2007-03-30       Impact factor: 2.408

Review 7.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 8.  PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Authors:  John A Katzenellenbogen
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

Review 9.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.